{
  "abstract": "Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing in prevalence worldwide. Pathogenesis of MASLD has been considerably heterogenous. Increased hepatic de novo lipogenesis, adipose tissue dysfunction, genetic predisposition, epigenetic mechanism, and other related factors have been associated with the development and progression of MASLD. Patients with MASLD are at high risk of not only adverse liver-related outcomes, including hepatocellular carcinoma, but also cardiometabolic disease including type 2 diabetes mellitus. Weight loss is the cornerstone of therapy among the various treatments for MASLD to decrease hepatic fat accumulation and delay the progression of inflammation and fibrosis. Resmetirom and semaglutide are approved for the treatment of metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis, and many drugs are under investigation. Careful attention should be paid to the screening of MASLD, and concerted efforts should be made to manage it appropriately.\n\nSee also the graphical abstract(Fig. 1).",
  "abstract_shown": true,
  "affiliations": [
    "Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea",
    "Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea",
    "Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea"
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 3,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Kyung-Soo Kim"
    },
    {
      "affs": [
        1
      ],
      "name": "Soo Lim"
    },
    {
      "affs": [
        2
      ],
      "name": "Cheol-Young Park"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/0rrqp5g032je2.bib",
  "cited_by": 0,
  "doi": "10.17179/excli2026-9310",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13731909/",
  "id": "0rrqp5g032je2",
  "issns": [
    "1611-2156"
  ],
  "landing_url": "https://doi.org/10.17179/excli2026-9310",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Review Article"
    ],
    [
      "openalex",
      "2721|Liver Disease Diagnosis and Treatment"
    ]
  ],
  "openalex": "W7214020286",
  "pdf_url": "https://www.excli.de/excli/article/download/9310/5849",
  "pmcid": "PMC13731909",
  "pmid": "42985147",
  "published": "2026-09-22",
  "publisher": "Leibniz Research Centre for Working Environment and Human Factors",
  "ris": "https://research.draconitic.com/paper/0rrqp5g032je2.ris",
  "sources": [
    {
      "first_seen": "2026-11-08T12:22:00Z",
      "native_id": "PMC13731909",
      "source": "pmc",
      "url": "https://doi.org/10.17179/excli2026-9310"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2721|Liver Disease Diagnosis and Treatment",
      "subfield": "general"
    }
  ],
  "title": "Metabolic dysfunction-associated steatotic liver disease: Pathogenesis, complications and pharmacological treatment",
  "title_text": "Metabolic dysfunction-associated steatotic liver disease: Pathogenesis, complications and pharmacological treatment",
  "type": "peer-reviewed",
  "updated_at": "2026-11-08T12:22:00Z",
  "url": "https://research.draconitic.com/paper/0rrqp5g032je2",
  "venue": "EXCLI Journal",
  "versions": []
}